Current Report · Items 2.02 · 8-K

Delcath Systems, Inc.

DCTHNASDAQEQUITYCurrent

Results of Operations and Financial Condition

Filed Feb 26, 2026Accepted Feb 26, 2026, 8:06 AM ESTCIK 872912Accession 0001628280-26-012004

Company context

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System (HDS) for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.

Current securities

DCTHNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 2.02

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 2.02 Results of Operations and Financial Condition. On February 26, 2026, Delcath Systems, Inc. (“Delcath”) issued a press release announcing financial results and business highlights for the year and quarter ended December 31, 2025 (the “Press Release”). A copy of the press release is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference. The information contained in this Current Report on Form 8-K, including the Press Release, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the Press Release shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission by Delcath whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Filed exhibits (1)

EX-99.1 (by filename) dcth-q425erex991.htm

EX-99.1 2 dcth-q425erex991.htm EX-99.1 Document Exhibit 99.1 Delcath Systems Reports Fourth Quarter and Full Year 2025 Results Conference Call Today at 8:30 a.m. Eastern Time QUEENSBURY, NY - February 26, 2026, Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2025. Fourth Quarter and Full Year 2025 Financial Results • Total fourth quarter and full year revenue of $20.7 million and $85.2 million, respectively ◦ HEPZATO KIT™ fourth quarter and full year revenue of $19.0 million and $78.8 million, respectively ◦ CHEMOSAT® fourth quarter and full year revenue of $1.7 million and $6.4 million, respectively • Gross margins of 85% for the fourth quarter and 86% for the full year • Fourth quarter net loss of $1.9 million and full year net income of $2.7 million • Non-GAAP positive adjusted EBITDA for the fourth quarter and full year of $2.4 million and $25.1 million, respectively • Repurchased 628,572 common shares for $6.0 million throug…

Open exhibit ↗